

Gregory D. Miller
Timothy P. Gonzalez
Marcus O. Tubin
RIVKIN RADLER LLP
25 Main Street
Court Plaza North, Suite 501
Hackensack, New Jersey 07601
Telephone: (201) 287-2460
Facsimile: (201) 489-0495
Gregory.Miller@rivkin.com
Timothy.Gonzalez@rivkin.com
Marcus.Tubin@rivkin.com

Samuel T. Lockner (to be admitted *pro hac vice*)
Gary J. Speier (to be admitted *pro hac vice*)
Seung Sub Kim (to be admitted *pro hac vice*)
CARLSON, CASPERS, VANDENBURGH & LINDQUIST, PA
Capella Tower, Suite 4200
225 South Sixth Street
Minneapolis, Minnesota 55402
Telephone: (612) 436-9600
Facsimile: (612) 436-9605
Slockner@carlsoncaspers.com
gspeier@carlsoncaspers.com
Ekim@carlsoncaspers.com

*Attorneys for Defendants Sun Pharmaceutical
Industries Limited and Sun Pharmaceutical
Industries, Inc.*

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

AMERICAN REGENT, INC.,

Plaintiff,

v.

SUN PHARMACEUTICAL INDUSTRIES
LIMITED AND SUN PHARMACEUTICAL
INDUSTRIES, INC.,

Defendants.

C.A. No.: 2:24-cv-07810-BRM-CLW

**SUN'S ANSWER, SEPARATE DEFENSES, AND
COUNTERCLAIMS TO COMPLAINT**

Defendants Sun Pharmaceutical Industries Limited (“SPIL”) and Sun Pharmaceutical Industries, Inc. (“SPINC”) (collectively, “Sun” or “Defendants”), by and through their undersigned attorneys, provide the following answers, separate defenses, and counterclaims to the Complaint (“Complaint”) (D.I. 1) of Plaintiff American Regent (“ARI” or “Plaintiff”). This pleading is based upon Sun’s knowledge as to its own activities, and upon information and belief as to other matters.

Pursuant to Fed. R. Civ. P. 8(b)(3), Sun denies all allegations in Plaintiff's Complaint except those specifically admitted below:

NATURE OF THE ACTION

1. The allegations in paragraph 1 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits Plaintiff purports to bring an action for patent infringement under the patent laws of the United States, 35 U.S.C. § 100 *et seq.* Sun admits to filing ANDA No. 219547 ("Sun's ANDA") with the FDA seeking approval of the product described therein ("Sun's Proposed ANDA Product") prior to the expiration of United States Patent No. 11,998,565 ("the '565 patent"). Sun admits that Sun's ANDA includes a Paragraph IV certification. Sun denies all further allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

THE PARTIES

2. Sun is without knowledge or information sufficient to form a belief as to the truth or falsity of the allegations in this paragraph of the Complaint and therefore denies the same.

3. Sun admits that Sun Pharmaceutical Industries Limited is a company organized and existing under the laws of India with a place of business at Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai 400063, India. Sun denies all further allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

4. Sun admits that Sun Pharmaceutical Industries, Inc. is organized under the laws of Delaware with a place of business located at 2 Independence Way, Princeton, New Jersey 08540. Sun denies all further allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

JURISDICTION AND VENUE

5. The allegations in paragraph 5 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits that Plaintiff purports to bring a civil action for patent infringement arising under the patent laws of the United States, 35 U.S.C. § 100 *et. seq.* Sun does not contest jurisdiction is proper under 28 U.S.C. §§ 1331 and 1338(a) for this matter. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

6. The allegations in paragraph 6 comprise conclusions of law to which no answer is required. To the extent a response is required, solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, SPIL does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

7. The allegations in paragraph 7 comprise conclusions of law to which no answer is required. To the extent a response is required, solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, SPINC does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

8. The allegations in paragraph 8 comprise conclusions of law to which no answer is required. To the extent a response is required, solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, SPIL does not contest personal jurisdiction, and expressly reserves the right to contest

personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

9. The allegations in paragraph 9 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits that SPINC has a place of business in Princeton, New Jersey. Solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, SPINC does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

10. The allegations in paragraph 10 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun denies the allegations in Paragraph 10.

11. The allegations in paragraph 11 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits that SPINC is the U.S. Agent for ANDA No. 219547. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

12. The allegations in paragraph 12 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits that SPINC is registered with the State of New Jersey's Division of Revenue and Enterprise Services as a business operating in New Jersey under Business ID No. 0101055400. Solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, Sun does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

13. The allegations in paragraph 13 comprise conclusions of law to which no answer is required. To the extent a response is required, solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, Sun does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

14. The allegations in paragraph 14 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits that SPIL has previously not contested personal jurisdiction in certain cases and has filed counterclaims in the District of New Jersey. Solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, Sun does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

15. The allegations in paragraph 15 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits that SPINC has previously not contested personal jurisdiction in certain cases and has filed counterclaims in the District of New Jersey. Solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, Sun does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

16. The allegations in paragraph 16 comprise speculation of future events and conclusions of law to which no answer is required. To the extent a response is required, solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, Sun does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint and specifically denies that "Sun has committed an act of patent infringement under 35 U.S.C. § 271(e)(2)," that it "intends a future course of conduct that includes acts of patent infringement in New Jersey," and that its "acts have led and will lead to foreseeable harm and injury to ARI in New Jersey." Allegations not expressly admitted are denied.

17. The allegations in paragraph 17 comprise conclusions of law to which no answer is required. To the extent a response is required, solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, Sun does not contest personal jurisdiction, and expressly reserves the right to contest personal jurisdiction in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

18. The allegations in paragraph 18 comprise conclusions of law to which no answer is required. To the extent a response is required, solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, Sun does not contest venue, and expressly reserves the right to contest venue in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

19. The allegations in paragraph 19 comprise conclusions of law to which no answer is required. To the extent a response is required, solely for the purposes of Plaintiff's claims against Sun in this case as they apply to Sun's Proposed ANDA Product described in Sun's ANDA No. 219547, Sun does not contest venue, and expressly reserves the right to contest venue in any other case as to any other part. Sun denies all remaining allegations in this paragraph of the Complaint and specifically that SPINC "has committed acts of infringement in New Jersey." Allegations not expressly admitted are denied.

20. The allegations in paragraph 20 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits that Sun has submitted ANDA No. 219547 to the FDA. Sun denies all remaining allegations in this paragraph of the Complaint.

21. The allegations in paragraph 21 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits that SPINC has a place of business at 2 Independence Way, Princeton, New Jersey 08540. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

22. Sun admits that SPIL, through its U.S. Agent SPINC, filed ANDA No. 219547. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

BACKGROUND

23. Sun admits that ARI is identified as the Applicant Holder of NDA No. 209379 according to Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the "Orange Book." Sun further admits that the Orange Book lists April 30, 2019 as the approval date for NDA No. 209379 for Selenious Acid (eq. 600 mcg Selenium/10 mL (eq. 60 mcg

Selenium/mL)). Sun lacks information or knowledge sufficient to form a belief as to the truth or falsity of the remaining allegations of this paragraph, and therefore denies the same.

24. The allegations in paragraph 24 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun lacks information or knowledge sufficient to form a belief as to the truth or falsity of the remaining allegations of this paragraph, and therefore denies the same.

25. Sun admits that Plaintiff purports to attach a copy of the '565 patent to the Complaint as Exhibit 1. Sun admits that the '565 patent states on its face that it was issued on June 4, 2024 and is titled "Trace element compositions, methods of making and use." Sun lacks information or knowledge sufficient to form a belief as to the truth or falsity of the remaining allegations of this paragraph, and therefore denies the same.

26. Sun admits that the '565 patent is listed in connection with Selenious Acid products in the Orange Book. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

27. Sun admits that the Orange Book indicates that the patent expiration date for the '565 patent is July 1, 2041. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

28. Sun admits that SPIL, through its U.S. Agent SPINC, filed ANDA No. 219547. Sun admits that ANDA No. 219547 includes a Paragraph IV certification. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

29. Sun admits that, on June 11, 2024, SPIL sent a letter ("Notice Letter") to Plaintiff. Sun admits that, according to the Notice Letter, SPIL seeks approval to engage in the commercial manufacture, use, importation, offer for sale or sale of Sun's Proposed ANDA Product prior to the

expiration of the '565 patent pursuant to the patent laws. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

30. Sun admits that Sun filed ANDA No. 219547. Sun admits that ANDA No. 219547 includes a Paragraph IV certification, alleging that the '565 patent is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of Sun's Proposed ANDA Product. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

31. Sun admits that Sun's ANDA No. 219547 identifies ARI Selenious Acid Injection, 600 mcg selenium/10 mL (eq. 60 mcg selenium/mL) as the reference listed drug. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

32. Sun admits that according to the Notice Letter, Sun's product is selenious acid injection USP, 600 mcg/10 mL (60 mcg/mL) of selenium in a 10 mL pharmacy bulk package. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

33. Sun admits that Sun's Proposed ANDA Product contains 600 mcg selenium/10 mL (60 mcg selenium/mL). Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

34. Sun admits that ANDA No. 219547 contains information demonstrating the bioequivalence of Sun's Proposed ANDA Product to the reference listed drug, which is ARI's Selenious Acid product. Sun lacks sufficient information to form a belief as to the truth of the allegations that relate to future events, and therefore deny them. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

COUNT I: INFRINGEMENT OF THE '565 PATENT

35. Sun realleges its answers to the allegations of paragraphs 1-34 as if fully set forth herein.

36. Denied.

37. Denied.

38. Denied.

39. Denied.

40. The allegations in paragraph 40 comprise conclusions of law to which no answer is required. To the extent a response is required, Sun admits it had knowledge of the '565 patent as of the time it submitted a Paragraph IV certification. Sun denies all remaining allegations in this paragraph of the Complaint. Allegations not expressly admitted are denied.

41. Denied.

PRAYER FOR RELIEF

Sun denies that Plaintiff is entitled to judgment or any of the relief sought against Sun in paragraphs (a)-(h) under the heading “PRAYER FOR RELIEF” in the Complaint. Sun demands judgment in its favor.

SEPARATE DEFENSES OF DEFENDANTS

Without prejudice to the denials set forth in its Answer, Sun pleads the following separate defenses in response to Plaintiff’s allegations. Sun reserves the right to allege any and all defenses not presently known or revealed during discovery or other analysis.

First Separate Defense

Count I is barred for failure to state a claim upon which relief can be granted.

Second Separate Defense

The claims of the '565 patent are invalid for failing to comply with one or more provisions of Title 35 of the United States Code, including but not limited to, §§ 101, 102, 103 and/or 112, and/or based on other judicially created bases for invalidation.

Third Separate Defense

Sun has not infringed, are not infringing, and will not infringe, literally or under the doctrine of equivalents, either directly or by contribution or inducement, any valid and enforceable claim of the '565 patent.

Fourth Separate Defense

Plaintiff may not seek injunctive relief against Sun for at least the reason that Plaintiff's alleged damages are not immediate or irreparable and Plaintiff therefore has an adequate remedy at law.

Fifth Separate Defense

Plaintiff has failed to allege any facts supporting this is an exceptional case or an award of attorneys' fees under 35 U.S.C. § 285 or otherwise. Plaintiff is not entitled to a finding that this case is exceptional under 35 U.S.C. § 285 or otherwise.

Sixth Separate Defense

Plaintiff lacks subject matter jurisdiction for any infringement claim under 35 U.S.C. § 271 (a), (b), and (c).

Additional Defenses

Sun reserves the right to allege additional separate defenses as they become known through the course of discovery.

COUNTERCLAIMS

Without admitting any of the allegations of Plaintiff/Counterclaim-Defendant American Regent, Inc. (“Plaintiff/Counterclaim-Defendant” or “ARI”) other than those expressly admitted herein, and without prejudice to Defendants/Counterclaim-Plaintiffs Sun Pharmaceutical Industries Limited (“SPIL”) and Sun Pharmaceutical Industries, Inc. (“SPINC”) (collectively, “Sun”) to plead additional counterclaims as the facts of the matter warrant, Sun asserts the following counterclaims against ARI:

NATURE OF THE ACTION

1. These Counterclaims arise under the patent laws of the United States, 35 U.S.C. § 1 *et seq.*, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202 and seek a declaratory judgment that Sun’s proposed products in Abbreviated New Drug Application (“ANDA”) No. 219547 do not and will not infringe any valid and enforceable claim of U.S. Patent No. 11,998,565 (“the ’565 patent” or “the patent-in-suit”), and that each and every claim of the ’565 patent is invalid for failure to satisfy one or more provisions of Title 35 of the United States Code, including but not limited to, 35 U.S.C. §§ 102, 103 and/or 112, and/or based on other judicially created bases for invalidation.

2. Upon information and belief, a true and complete copy of the ’565 patent is attached to the Complaint (D.I. 1) as Exhibit 1.

PARTIES

3. Defendant/Counterclaim-Plaintiff SPIL is a company incorporated under the laws of India, having a principal place of business in Mumbai, India.

4. Defendant/Counterclaim-Plaintiff SPINC is a company incorporated under the laws of the state of Delaware, having places of business in Princeton, New Jersey and Cranbury, New Jersey.

5. On information and belief, and based on Plaintiff/Counterclaim-Defendant's allegations, Plaintiff/Counterclaim-Defendant ARI is a corporation organized and existing under the laws of the State of New York, with a principal place of business at 5 Ramsey Road, Shirley, New York 11967.

6. ARI purports to be the lawful owner of the '565 patent.

7. ARI purports to hold the New Drug Application ("NDA") No. 209379 for Selenious Acid ((1) eq. 600 mcg Selenium/10 mL (eq. 60 mcg Selenium/mL), (2) eq. 60 mcg Selenium/mL (eq. 60 mcg Selenium/mL), and (3) eq. 12 mcg Selenium/2 mL (eq. 6 mcg Selenium/mL)) and purports to market, distribute, and sell the selenious acid products.

JURISDICTION AND VENUE

8. This Court has subject matter jurisdiction over these Counterclaims for declaratory judgment pursuant to 28 U.S.C. §§ 1331, 1337(a), 1338(a), 2201(a) and (b), and 2202 based on an actual controversy among the parties, arising under the patent laws of the United States, 35 U.S.C. § 1 *et seq.*

9. This Court has personal jurisdiction over Plaintiff/Counterclaim-Defendant based on, *inter alia*, its filing of this lawsuit in this jurisdiction, and/or Plaintiff/Counterclaim-Defendant's substantial business in and regular systematic contact with this District. Counterclaim-defendant has also availed itself of this forum in other pending actions, *e.g.*, *American Regent, Inc. v. Gland Pharma Limited*, Civil Action No. 2-24-cv-07756; *American Regent, Inc. v. Zydus Pharmaceuticals (USA) Inc.*, Civil Action No. 2-24-cv-07812.

10. Venue is proper in this judicial district based on 28 U.S.C. §§ 1391 and 1400 and 21 U.S.C. § 355(j)(5)(C)(i)(II).

BACKGROUND

11. According to the United States Food & Drug Administration (“FDA”) publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (“the Orange Book”), ARI holds an approved New Drug Application (“NDA”) No. 209379 for selenious acid solutions.

12. Under 21 U.S.C. § 355(b)(1), an NDA holder must provide to FDA the patent numbers and expiration dates of any patent(s) that the NDA holder believes “claims the drug for which the applicant submitted the [NDA]” or which “claims a method of using such drug.” FDA ministerially publishes these patents in the Orange Book.

13. Upon information and belief, and as stated in the Complaint in this matter, ARI is the owner of the ’565 patent. Upon information and belief, and as stated on the face of the ’565 patent, ARI is the assignee of the ’565 patent.

14. Upon information and belief, ARI, itself or through its agents, caused the ’565 patent to be listed in the Orange Book as a patent that claims its selenious acid products or a method of using its selenious acid products.

15. The ’565 patent, on its face, is titled “Trace element compositions, methods of making and use” and has an issue date of June 4, 2024.

16. SPIL submitted ANDA No. 219547 to FDA seeking approval to engage in commercial manufacture, or sale of the products described therein (“Sun’s Proposed ANDA Product”) in the United States. SPINC is the U.S. Agent for SPIL for ANDA No. 219547.

17. ANDA No. 219547 contains a certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) that the ’565 patent is invalid, unenforceable, and/or will not be infringed by

the commercial manufacture, use, offer for sale, sale, or importation into the United States of Sun's Proposed ANDA Product.

18. On or around June 11, 2024, SPIL sent a notice letter providing notice of its submission of ANDA No. 219547 to FDA ("the Notice Letter") to ARI. The Notice Letter contains notification of SPIL's Paragraph IV Certification to FDA that the '565 patent is invalid, unenforceable, and/or not infringed by Sun's Proposed ANDA Product and the factual and legal bases in support thereof. The Notice Letter also contained an offer of confidential access to ANDA No. 219547 in accordance with 21 U.S.C. § 355(j)(5)(C).

19. On or around July 16, 2024, Plaintiff/Counterclaim-Defendant filed a lawsuit, alleging, *inter alia*, infringement of the '565 patent based on SPIL's filing of ANDA No. 219547.

20. Sun denies it infringes any valid claim of the '565 patent.

21. Absent a ruling from this Court finding the '565 patent is invalid, unenforceable, and/or not infringed by Sun or the products described in ANDA No. 219547, ARI will continue to assert the '565 patent against Sun, hindering the ability of Sun to obtain regulatory approval and to market in the United States the products described in ANDA No. 219547, causing irreparable harm to Sun's businesses and denying Sun patent certainty.

22. ARI has requested both injunctive relief and damages against Sun. Sun has invested significant financial and other resources into the development of Sun's Proposed ANDA Product and in seeking FDA approval. ARI's threats against Sun will continue as long as the disputes identified with respect to the infringement and validity of the '565 patent remain.

23. Accordingly, there is an actual, substantial, and continuing justiciable case and controversy between ARI and Sun regarding the '565 patent, over which this Court can and should exercise jurisdiction and declare the rights of the parties.

COUNT I
(Declaration of Invalidity of the '565 Patent)

24. Sun incorporates by reference Paragraphs 1 through 23 as if fully set forth herein.

25. This Counterclaim arises under the patent laws of the United States, 35 U.S.C. § 1 *et seq.*, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. An actual, substantial, and continuing justiciable controversy having adverse legal interest of sufficient immediacy and reality to warrant the issuance of a declaration of rights by the Court exists between Sun and ARI concerning the invalidity of the '565 patent.

26. One or more of the claims of the '565 patent is invalid for failure to comply with one or more of the requirements set forth in 35 U.S.C. §§ 101, 102, 103, and/or 112, and/or other judicially created bases for invalidity.

27. Pursuant to Federal Rule of Civil Procedure 57 and 28 U.S.C. §§ 2201 *et seq.*, Sun is entitled to a declaratory judgment that one or more claims of the '565 patent is/are invalid.

COUNT II
(Declaration of Non-Infringement of the '565 Patent)

28. Sun incorporates by reference Paragraphs 1 through 27 as if fully set forth herein.

29. This Counterclaim arises under the patent laws of the United States, 35 U.S.C. § 1 *et seq.*, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202. An actual, substantial, and continuing justiciable controversy having adverse legal interest of sufficient immediacy and reality to warrant the issuance of a declaration of rights by the Court exists between Sun and ARI concerning the non-infringement of the '565 patent.

30. Neither the submission of Sun's ANDA nor any future manufacture, use, sale, offer for sale, and/or importation into the United States of Sun's Proposed ANDA Product infringes (or will infringe), induces (or will induce) infringement of, or contributes (or will contribute) to the

infringement of any valid or enforceable claim of the '565 patent, either literally or under the doctrine of equivalents, at least because the claims of the '565 patent are invalid, and an invalid claim cannot be infringed.

31. Additionally, for at least the reasons set forth in the Notice Letter of June 11, 2024, neither the submission of Sun's ANDA nor the manufacture, use, sale, offer for sale, and/or importation into the United States of Sun's Proposed ANDA Product infringes (or will infringe), induces (or will induce) infringement of, or contributes (or will contribute) to the infringement of any valid or enforceable claim of the '565 patent, either literally or under the doctrine of equivalents, at least because Sun's Proposed ANDA Product is not covered by the claims of the '565 patent.

32. Pursuant to Federal Rule of Civil Procedure 57 and 28 U.S.C. § 2201 *et seq.*, Sun is entitled to a declaratory judgment that it has not, does not, and will not infringe, either directly or indirectly, any valid and enforceable claim of the '565 patent, either literally or under the doctrine of equivalents.

EXCEPTIONAL CASE

This case is an exceptional one, and Sun is entitled to an award of its reasonable attorney fees, expenses, and costs under 35 U.S.C. § 285.

PRAYER FOR RELIEF

WHEREFORE, Sun respectfully requests the Court enter judgment in its favor, granting the following relief:

- A. Dismissing the Complaint, with prejudice, and deny Plaintiff the reliefs requested in the Complaint and any relief whatsoever;
- B. Deny Plaintiff any award of damages, costs, or fees;

- C. Declaration that Sun has not and will not infringe any valid and enforceable claim of the '565 patent;
- D. Declaration that all claims of the '565 patent are invalid;
- E. Declaration that all claims of the '565 patent are not infringed and will not be infringed by the submission of Sun's ANDA or the manufacture, use, sale, offer for sale, marketing, or importation into the United States of Sun's Proposed ANDA Product;
- F. Declaration that this is an exceptional case in favor of Sun under 35 U.S.C. § 285;
- G. Declaration that Sun is the prevailing party and awarding its fees, costs, and expenses in this action pursuant to 35 U.S.C. § 285, or any other applicable statute or law;
- H. An award to Sun of its costs and expenses in this action pursuant to 28 U.S.C. § 1920, or any other applicable statute; and
- I. An award to Sun of such other and further relief as the Court deems just and proper.

Dated: August 23, 2024

s/ Gregory D. Miller

Gregory D. Miller

Timothy P. Gonzalez

Marcus O. Tubin

RIVKIN RADLER LLP

25 Main Street

Court Plaza North, Suite 501

Hackensack, New Jersey 07601

Telephone: (201) 287-2460

Facsimile: (201) 489-0495

Gregory.Miller@rivkin.com

Timothy.Gonzalez@rivkin.com

Marcus.Tubin@rivkin.com

Of Counsel:

Samuel T. Lockner (to be admitted *pro hac vice*)

Gary J. Speier (to be admitted *pro hac vice*)

Seung Sub Kim (to be admitted *pro hac vice*)

**CARLSON, CASPERS, VANDENBURGH &
LINDQUIST, P.A.**

225 S. Sixth Street, Suite 4200

Minneapolis, MN 55402

Telephone: (612) 436-9600

slockner@carlsoncaspers.com

gspeier@carlsoncaspers.com

ekim@carlsoncaspers.com

*Attorneys for Defendant Sun Pharmaceutical
Industries, Ltd. and Sun Pharmaceuticals Inc.*

LOCAL CIVIL RULE 11.2 and 40.1 CERTIFICATION

Pursuant to Local Civil Rule 11.2 and 40.1, I hereby certify that, to the best of my knowledge, the matter in controversy is not the subject of any other action pending in any court, or of any pending arbitration or administrative proceeding.

Dated: August 23, 2024

s/ Gregory D. Miller
Gregory D. Miller

LOCAL CIVIL RULE 201.1 CERTIFICATION

I hereby certify that the above-captioned matter is not subject to compulsory arbitration in that the parties seek, *inter alia*, injunctive and declaratory relief in their respective pleadings.

I hereby certify under penalty of perjury that the foregoing is true and correct.

Dated: August 23, 2024

s/ Gregory D. Miller
Gregory D. Miller

CERTIFICATE OF SERVICE

I hereby certify that, on August 23, 2024, the foregoing document described as **DEFENDANTS' ANSWER TO COMPLAINT, SEPARATE DEFENSES AND COUNTERCLAIMS** was served on all counsel of record indicated below via electronic mail.

Charles H. Chevalier
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102-5310
(973) 596-4611
cchevailier@gibbonslaw.com

Christine A. Gaddis
GIBBONS P.C.
141 West Front Street, Suite 240
Red Bank, New Jersey 07701
(732) 704-5801
cgaddis@gibbonslaw.com

OF COUNSEL
Dennies Varughese, Pharm. D.
Uma Everett (pro hac vice to be filed)
Adam LaRock (pro hac vice to be filed)
Alex Alfano (pro hac vice to be filed)
Ryan Conkin (pro hac vice to be filed)
**STERNE, KESSLER, GOLDSTEIN &
FOX P.L.L.C.**
1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600
dvarughese@sternekessler.com
ueverett@sternekessler.com
alarock@sternekessler.com
aalfano@sternekessler.com
rconkin@sternekessler.com

Attorneys for Plaintiff, American Regent, Inc.

s/ Gregory D. Miller
Gregory D. Miller